MARC Mid-Atlantic Renal Coalition
300 Arboretum Place   Suite #310
Richmond, VA 23236
Phone: 804.320.0004
Fax: 804.320.5918
Patient Toll Free 866.651.6272
marc@nw5.esrd.net
HomeAbout UsClinicalDataEducationPatients & FamiliesNewsContact Us
Clinical > Alerts & Recalls

Alerts & Recalls 

The U.S. Food and Drug Administration (FDA), in addition to private companies, often issue product recalls, reviews, and/or advisories that affect the dialysis community. Some recalls may relate to equipment malfunctions or hazards, or even medication administration or dosage. MARC relays all recalls or warning as we are apprised. Methods of notification include, but are not limited to, posting links to the appropriate notice on the MARC website; emailing, faxing, or mailing notices to facility personnel; and publication in the Network's e-lerts and/or REMARCS newsletters.

Below are links to the most recent recalls, reviews, and advisories affecting the dialysis community:

January

 
Novartis Issues Voluntary Recall of Excedrin and NoDoz Products Expiring on/before December 20, 2014 and Bufferin and Gas-X Prevention Products Expiring on/before December 20, 2013 Due to Foreign, Chipped, or Broken Tablets/Gelcaps

Class I Recall:  Cardiac Science Corporation and Its Distributors Recall
  • Cardio Science Powerheart, CardioVive, CardioLife;
  • GE Responder and Responder Pro; and
  • Nihon-Kohden Automated External Defibrillators (AEDs)

Due to a defect, the systems may fail unexpectedly.
*A Class I Recall is defined as a situation where there is reasonable probability that the use of or exposure to a product will cause serious adverse effects or even death.



February


Important Safety Labeling Change: Statin Drugs

Safety Labeling Changes Approved by the FDA - February 2012


March


Important Drug Safety Communication:  Interactions Between Statins and Some HIV or Hepatitis C Drugs Can Increase Muscle Injury Risk

Mercury Poisoning: Linked to Skin Products

Safety Labeling Changes Approved by the FDA – March 2012


April

Class I Recall:  Thoratec Corporation Recalls HeartMate II Left Ventricular Assist System (LVAS) Due to Kinking or Deforming of Outflow Graft
*A Class I Recall is defined as a situation where there is reasonable probability that the use of or exposure to a product will cause serious adverse effects or even death.

American Regent Recalls Cyanocobalamin Injection, USP, 1000 mcg/mL, 1 ml Vial Lot #s 1662, 1679, and 1683 Due to Cracked Vials

FDA Issues New Warning & Contraindication for Renal Patients Taking Medicines Containing Aliskiren (Tekturna)

FDA Revises Drug Safety Information for Victrelis (Boceprevir) 


This website is
Section 508 Compliant.

Documents are presented in Adobe PDF; click here to download free Adobe Reader.

Powered by Kentico CMS